ALNYLAM PHARMACEUTICALS, INC. (ALNY) Operating cash flow 2016–2025
ALNYLAM PHARMACEUTICALS, INC. (ALNY) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
$524.1MFY2025 · since FY2016: -$307.7M → $524.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $524.1M | +6405.1% |
| FY2024 | -$8.3M | -108.0% |
| FY2023 | $104.2M | +119.2% |
| FY2022 | -$541.3M | +15.6% |
| FY2021 | -$641.7M | -4.3% |
| FY2020 | -$615.0M | -120.9% |
| FY2019 | -$278.4M | +50.5% |
| FY2018 | -$562.6M | -47.0% |
| FY2017 | -$382.8M | -24.4% |
| FY2016 | -$307.7M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More ALNY financial trends
ALNY RevenueALNY Net incomeALNY Net marginALNY Gross profitALNY Gross marginALNY Operating incomeALNY Operating marginALNY Free cash flowALNY Capital expendituresALNY Return on equityALNY Stock buybacksALNY Dividends paidALNY Total assetsALNY Total liabilitiesALNY Shareholders’ equityALNY overview →